Sascha Tuchman

11PUBLICATIONS
53CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Accelerators
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 27, 2026
Treatment Initiation Among Black and White Older Adults With Multiple Myeloma: A SEER-Medicare Analysis.

Matthew R LeBlanc, Xi Zhou, Christopher D Baggett

|Jun 26, 2025
Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies.

Ping Zhou, Mahesh M Mansukhani, Raymond Yeh

|Jul 26, 2024
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.

Peter Voorhees, Vera Suman, Yvonne Efebera

|Dec 16, 2022
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy.

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory S Calip

|Dec 06, 2022
Cross-Sectional Analysis of Clinical Trial Availability and North Carolina Neighborhood Social Vulnerability.

Shakira J Grant, Matthew Jansen, Tzy-Mey Kuo

|Dec 03, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.

Carlos Fernández de Larrea, Robert Kyle, Laura Rosiñol

Pageof 2

Frequent Collaborators

4 joint publications

Jacob P Laubach

2 joint publications

Paul G Richardson

2 joint publications

Saad Z Usmani

1 joint publications

Robert A Redd